New therapeutic evidence has demonstrated that umbilical cord-derived mesenchymal stem cells (MSCs) can safely and effectively improve motor and comprehensive function in children with cerebral palsy (CP).
In addition to standard rehabilitation, a group of 39 children with cerebral palsy received four transfusions of umbilical cord MSCs intravenously, while the control group received a placebo. After a 12-month follow-up phase all patients were assessed for comprehensive function, gross motor function and other indicators of progress.
Clinical data showed that the umbilical cord MSC transplantation was safe and effective at increasing motor and comprehensive function in the group. The researchers have highlighted that the dosage and therapeutic window used in this trial were also significant enough for reference in future clinical applications.
Cerebral palsy is a lifelong neurological disorder that affects a person’s ability to move, balance and coordinate their body. This is caused by brain damage or lack of development that often occurs during or after birth. It’s estimated that 1 in 400 babies born with the disorder.
This clinical trial adds to growing evidence around the benefits for umbilical cord stem cells for treating cerebral palsy. You can read more about this in our guide to stem cell therapy and cerebral palsy.